Fig. 2. Cumulative incidence of sustained ≥2-step DRSS improvement from baseline through week 100.

DRSS was assessed at baseline and at weeks 24, 52, 72, and 100. DRSS Diabetic Retinopathy Severity Scale, PYR patient-years at risk, HR hazard ratio, IAI intravitreal aflibercept injection, NE not estimable, 2q4 2 mg q4 weeks, 2q8 2 mg q8 weeks after 5 initial monthly doses.